Under behandling med NeoRecormon er det på grund af øget erytrocytvolumenfraktion ofte nødvendigt at øge heparindosis under hæmodialyse hos patienter med kronisk nyresvigt.
In chronic renal failure patients an increase in heparin dose during haemodialysis is frequently required during the course of therapy with NeoRecormon as a result of the increased packed cell volume.